Production (Stage)
Kairos Pharma, Ltd.
KAPA
$0.5271
$0.054111.44%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.78% | 6.40% | -313.83% | 21.67% | 71.11% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -100.00% | 505.26% | -- | -- |
| Total Other Non-Cash Items | 130.04% | -144.31% | -- | -- | -97.81% |
| Change in Net Operating Assets | 170.82% | 64.10% | -6,634.62% | -91.30% | 45.85% |
| Cash from Operations | 60.40% | 10.74% | -1,102.38% | -566.67% | -45.45% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -60.78% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -840.43% | 152.81% | -23.61% |
| Cash from Financing | 2,253.52% | -102.72% | 3,400.67% | 267.42% | -23.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.51% | -160.86% | 16,921.05% | 64.15% | -783.33% |